Tyra Biosciences, Inc. (TYRA)
- Previous Close
14.66 - Open
14.60 - Bid 14.65 x 100
- Ask 14.83 x 100
- Day's Range
14.35 - 14.82 - 52 Week Range
10.38 - 20.67 - Volume
122,074 - Avg. Volume
138,624 - Market Cap (intraday)
774.685M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-1.62 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.60
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
tyra.bioRecent News: TYRA
Performance Overview: TYRA
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TYRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TYRA
Valuation Measures
Market Cap
769.96M
Enterprise Value
572.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-7.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.31%
Return on Equity (ttm)
-29.92%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.13M
Diluted EPS (ttm)
-1.62
Balance Sheet and Cash Flow
Total Cash (mrq)
203.47M
Total Debt/Equity (mrq)
3.18%
Levered Free Cash Flow (ttm)
-29.49M